Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BeOne Medicines Ltd. - American Depositary Shares (NQ:ONC)

287.85 -1.90 (-0.66%)
Streaming Delayed Price Updated: 3:27 PM EDT, Aug 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about BeOne Medicines Ltd. - American Depositary Shares

< Previous 1 2 Next >
Earnings Scheduled For August 8, 2025
 
Via Benzinga
A Glimpse of BeiGene's Earnings Potential
 
Via Benzinga
BeOne Medicines (ONC) Q2 EPS Soars 924%
Via The Motley Fool
Earnings Scheduled For August 6, 2025
 
Via Benzinga
BeiGene's Earnings: A Preview
 
Via Benzinga
Earnings Preview: BeiGene
 
Via Benzinga
Earnings Scheduled For May 7, 2025
 
Via Benzinga
Earnings Scheduled For February 27, 2025
 
Via Benzinga
Deep Dive Into BeOne Medicines Stock: Analyst Perspectives (9 Ratings)
 
Via Benzinga
AstraZeneca In $15B Talks For Drug That Could Upend Lung Cancer Treatment
Via Benzinga
What 8 Analyst Ratings Have To Say About BeOne Medicines
 
Via Benzinga
AppLovin, First Solar And Li Auto Are Among Top 10 Large Cap Losers Last Week (June 16-20): Are The Others In Your Portfolio?
Top 10 worst performing large-cap stocks last week: APP, FSLR, JHX, ONC, GSK, ACN, ANET, LI, CPAY, MA. Reasons include short-sell report, tax bill, and market selloff. 
Via Benzinga
CureVac, TELUS International, Oracle And Other Big Stocks Moving Higher On Thursday
 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030
Via The Motley Fool
Topics Economy Law Enforcement
Chinese Biotech BeiGene Stock Falls Despite Strong Brukinsa Sales And Earnings Beat
BeiGene posted a surprise Q1 profit and $1.12 billion in revenue, with strong U.S. Brukinsa sales, while reaffirming its 2025 outlook and margin guidance. 
Via Benzinga
Earnings Scheduled For May 14, 2025
 
Via Benzinga
Benzinga Bulls And Bears: Netflix, Novavax, Intel — And The Market Begins To Bounce Back
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories. 
Via Benzinga
Summit Therapeutics Retail Traders Stoked As Stock Surges On Promising Cancer Drug Trial
The study was conducted across multiple centers in China, comparing ivonescimab plus chemotherapy against tislelizumab (marketed as Tevimbra by BeiGene) plus chemotherapy. 
Via Stocktwits
Why Is Summit Therapeutics Stock Soaring On Wednesday?
Summit and Akeso report Phase 3 success as ivonescimab shows PFS gains in NSCLC trial, with new studies and collaborations underway. 
Via Benzinga
Fastenal Posts Better-Than-Expected Sales, Joins Simulations Plus, Certara And Other Big Stocks Moving Higher On Friday
 
Via Benzinga
Forecasting The Future: 4 Analyst Projections For BeiGene
 
Via Benzinga
This Reddit Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
 
Via Benzinga
BeiGene Discontinues Lung Cancer Drug Study After Interim Data Showed Limited Survival Benefit
BeiGene ends its Phase 3 lung cancer trial for ociperlimab after a futility analysis. No new safety concerns were found, and study results will be shared later. 
Via Benzinga
Why Greenland Technologies Shares Are Trading Higher By Around 89%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer
Leap Therapeutics' Phase 2 trial data show sirexatamab boosts response rates and survival in MSS colorectal cancer, with ongoing business development plans. 
Via Benzinga
EXCLUSIVE: Indaptus Therapeutics Starts Phase 1 Combination Study of Decoy20 With BeiGene's Cancer Drug For Advanced Solid Tumors
Indaptus advanced its Decoy20 trial to test a combination with tislelizumab, aiming to enhance checkpoint inhibitor effectiveness in cancer treatment. 
Via Benzinga
Earnings Scheduled For March 7, 2025
 
Via Benzinga
China-Based Biotech BeiGene Scores FDA Approval For Tevimbra/Chemo Combo For Untreated Patients With Esophageal Cancer
BeiGene's Tevimbra wins FDA approval for first-line metastatic ESCC treatment, showing significant survival benefits in PD-L1-positive patients. 
Via Benzinga
Alibaba, Super Micro Computer And XPeng Are Among Top 10 Large Cap Gainers Last Week (Feb 17-Feb 21): Are The Others In Your Portfolio?
Top performing large-cap stocks in the last week: Unity, Super Micro Computer, Alibaba, FTAI Aviation, STMicroelectronics, XPeng, Analog Devices, BeiGene, Tencent Music, Microchip Technology. 
Via Benzinga
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.